OTC •
Healthcare •
Biotechnology •
Quote as of 08/18/2026 13:44
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization2.83 mln
Float113 mln
Earnings Date08/11/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
28
/ 100
Underperforming
Debt / Equity
-0.28
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
BioxTran is a clinical-stage pharmaceutical company based in Needham, Massachusetts, working to develop treatments for viral infections, oxygen deficiency, and degenerative diseases. Its lead candidate, BXT-25, is a small molecule that carries oxygen using stabilized bovine hemoglobin, designed to help stroke patients and improve wound healing by restoring oxygen to affected tissue. The company is also developing ProLectin, a pectin-derived compound that targets galectin-3 to treat mild to moderate COVID-19. In partnership with the University of Minnesota, BioxTran is advancing a broader range of carbohydrate-based medicines since its founding in 2008.
